| 35.33 1.03 (3%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.58 |
1-year : | 48.56 |
| Resists | First : | 35.59 |
Second : | 41.58 |
| Pivot price | 33.72 |
|||
| Supports | First : | 30.24 |
Second : | 26.93 |
| MAs | MA(5) : | 34.51 |
MA(20) : | 33.01 |
| MA(100) : | 30.7 |
MA(250) : | 32.97  |
|
| MACD | MACD : | 1.2 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 84.5 |
D(3) : | 82.6 |
| RSI | RSI(14): 68.3 |
|||
| 52-week | High : | 46.47 | Low : | 25.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TGTX ] has closed below upper band by 9.3%. Bollinger Bands are 2.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.64 - 35.78 | 35.78 - 35.9 |
| Low: | 34.37 - 34.54 | 34.54 - 34.69 |
| Close: | 35.03 - 35.31 | 35.31 - 35.56 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Wed, 15 Apr 2026
Did Phase 3 Subcutaneous BRIUMVI Enrollment Just Redefine TG Therapeutics' (TGTX) MS Strategy? - simplywall.st
Wed, 15 Apr 2026
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI - Yahoo! Finance Canada
Wed, 15 Apr 2026
MS trial completion moves TG closer to at-home BRIUMVI option - Stock Titan
Sat, 04 Apr 2026
TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum - ChartMill
Tue, 10 Mar 2026
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) - Yahoo Finance
Mon, 23 Feb 2026
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 160 (M) |
| Shares Float | 141 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 65.9 (%) |
| Shares Short | 28,150 (K) |
| Shares Short P.Month | 29,310 (K) |
| EPS | 2.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.51 |
| Profit Margin | 72.5 % |
| Operating Margin | 26.2 % |
| Return on Assets (ttm) | 9.3 % |
| Return on Equity (ttm) | 102.7 % |
| Qtrly Rev. Growth | 78 % |
| Gross Profit (p.s.) | 3.22 |
| Sales Per Share | 3.85 |
| EBITDA (p.s.) | 0.77 |
| Qtrly Earnings Growth | -6.1 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | 12.75 |
| PEG Ratio | 0 |
| Price to Book value | 7.81 |
| Price to Sales | 9.15 |
| Price to Cash Flow | -227.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|